US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
AAPL
$333.69
▲+1.02%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
AAPL
$333.69
▲+1.02%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
INmune Bio Inc. - Common stock
(NQ:
INMB
)
1.930
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about INmune Bio Inc. - Common stock
< Previous
1
2
3
4
Next >
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
September 14, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio to Present at the H.C. Wainwright Global Investment Conference
September 09, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
August 26, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
July 31, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
July 31, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
July 30, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
July 20, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
July 15, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
July 09, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
July 01, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
June 25, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
June 23, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
June 02, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
May 15, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
May 14, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point
May 13, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases
May 05, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
April 30, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models
April 16, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
March 24, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
March 19, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
February 23, 2026
Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
February 19, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
February 12, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
February 10, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
January 27, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
December 05, 2025
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients
December 01, 2025
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
November 18, 2025
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
October 23, 2025
From
INmune Bio, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
